Public Profile

Corium, LLC

Corium, LLC, headquartered in the United States, is a leading innovator in the pharmaceutical industry, specialising in advanced drug delivery systems. Founded in 2010, the company has made significant strides in developing unique transdermal and microneedle technologies that enhance patient compliance and therapeutic efficacy. With a focus on transforming the way medications are administered, Corium's core products include its proprietary transdermal patches and microneedle arrays, which stand out for their precision and effectiveness. The company operates primarily in North America, with a growing presence in international markets. Recognised for its commitment to quality and innovation, Corium has achieved notable milestones, including strategic partnerships with major pharmaceutical firms. This positions Corium, LLC as a key player in the evolving landscape of drug delivery solutions, dedicated to improving patient outcomes through cutting-edge technology.

DitchCarbon Score

How does Corium, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

29

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Corium, LLC's score of 29 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

0%

Let us know if this data was useful to you

Corium, LLC's reported carbon emissions

In 2023, Corium, LLC reported significant carbon emissions, totalling approximately 12,297,884,000 kg CO2e for Scope 1, 214,545,000 kg CO2e for Scope 2, and 51,662,433,000 kg CO2e for Scope 3 emissions. This data highlights the company's comprehensive emissions profile, with Scope 3 emissions representing a substantial portion of their total emissions. In 2022, the company recorded emissions intensity of about 454,850 kg CO2e per unit of revenue for Scope 1 and 2 combined. The emissions intensity improved in 2023, with a reported value of approximately 2,000 kg CO2e per unit of revenue, indicating a positive trend towards reducing emissions relative to their sales turnover. Despite these figures, Corium, LLC has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented climate pledges or science-based targets suggests that while the company is aware of its emissions, it may not yet have formalised commitments to reduce them in line with industry standards. Overall, Corium, LLC's emissions data underscores the importance of establishing clear climate commitments and reduction strategies to address their significant carbon footprint effectively.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2023
Scope 1
12,297,884,000
Scope 2
214,545,000
Scope 3
51,662,433,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Corium, LLC's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Corium, LLC is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Corium, LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Zevra Therapeutics, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

DMK Pharmaceuticals Corporation

US
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Shionogi

JP
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Tris Pharma, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated about 2 hours ago

Supernus Pharmaceuticals, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Abbvie

US
Chemicals nec
Updated 1 day ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers